Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2020 08:01 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Reports Fourth Quarter and Full-Year 2019 Financial Results and Provides Recent Business Highlights

Recently Initiated PB2452 Phase 3 Trial for the Reversal of the Antiplatelet Effects of Ticagrelor Received FDA Breakthrough Therapy Designation and EMA PRIME Designation for PB2452 Secured PB2452...
February 26, 2020 16:01 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio to Present at Cowen and Company 40th Annual Health Care Conference

MALVERN, Pa. and SAN DIEGO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
February 13, 2020 16:01 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Appoints Alex C. Sapir to Board of Directors

MALVERN, Pa. and SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
February 11, 2020 08:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces European Regulatory Update for PB2452

PB2452 granted PRIME Designation by the European Medicines Agency PhaseBio receives written scientific advice confirming PB2452 clinical development plan In Phase 1 and Phase 2a clinical trials,...
February 04, 2020 16:01 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces Case Study Highlighting PB1046 Hemodynamic Data Presented at the 14th Pulmonary Vascular Research Institute World Congress

MALVERN, Pa. and SAN DIEGO, Calif., Feb. 04, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
January 13, 2020 16:01 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces Acquisition of Novel Oral Aldosterone Synthase Inhibitor to Develop for Treatment-Resistant Hypertension

MALVERN, Pa. and SAN DIEGO, Jan. 13, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
January 10, 2020 09:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Announces Financing and Co-Development Collaboration with SFJ Pharmaceuticals® for PB2452

PhaseBio to receive up to $120 million in development funding PhaseBio retains exclusive worldwide commercial rights to PB2452 MALVERN, Pa. and SAN DIEGO, Jan. 10, 2020 (GLOBE NEWSWIRE) --...
November 15, 2019 08:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio to Present at Stifel 2019 Healthcare Conference

MALVERN, Pa. and SAN DIEGO, Calif., Nov. 15, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...
November 14, 2019 08:00 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio Reports Third Quarter 2019 Financial Results and Recent Corporate Progress

Received Written End-of-Phase 1 Meeting Minutes Outlining Clear Development Path for PB2452 Completed Phase 2a Trial of PB2452 in Older and Elderly Subjects on Dual Antiplatelet Therapy Initiated...
November 07, 2019 16:01 ET | Source: PhaseBio Pharmaceuticals, Inc.

PhaseBio To Report Third Quarter 2019 Financial Results and Recent Corporate Progress on November 14, 2019

MALVERN, Pa. and SAN DIEGO, Nov. 07, 2019 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and...